Renoprotective effects of dulaglutide in patients with T2DM and CKD
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Standard
Renoprotective effects of dulaglutide in patients with T2DM and CKD. / Sorensen, Charlotte M; Holst, Jens J.
I: Nature Reviews. Nephrology, Bind 14, Nr. 11, 2018, s. 659-660.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Renoprotective effects of dulaglutide in patients with T2DM and CKD
AU - Sorensen, Charlotte M
AU - Holst, Jens J
PY - 2018
Y1 - 2018
N2 - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.
AB - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.
U2 - 10.1038/s41581-018-0055-x
DO - 10.1038/s41581-018-0055-x
M3 - Comment/debate
C2 - 30171207
VL - 14
SP - 659
EP - 660
JO - Nature Reviews Nephrology
JF - Nature Reviews Nephrology
SN - 1759-5061
IS - 11
ER -
ID: 203862373